Moderna Inc (MRNA)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -3,607,000 | -3,942,000 | 9,575,000 | 13,285,000 | -744,513 |
| Revenue | US$ in thousands | 3,236,000 | 6,848,000 | 19,263,000 | 17,736,000 | 274,490 |
| Pretax margin | -111.46% | -57.56% | 49.71% | 74.90% | -271.24% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $-3,607,000K ÷ $3,236,000K
= -111.46%
The pretax margin of Moderna Inc has shown significant fluctuations over the years based on the provided data. In December 31, 2020, the company had a negative pretax margin of -271.24%, indicating that its expenses exceeded its revenues before accounting for taxes.
However, by December 31, 2021, Moderna had turned its performance around with a strong pretax margin of 74.90%, indicating a significant improvement in profitability. This positive trend continued into December 31, 2022, with a pretax margin of 49.71%, although slightly lower than the previous year.
In December 31, 2023, the pretax margin took a negative turn again, falling to -57.56%. This decrease in profitability could signal challenges or increased expenses impacting the company's financial performance.
By December 31, 2024, Moderna's pretax margin further deteriorated to -111.46%, indicating significant losses before taxes. This sharp decline in profitability raises concerns about the company's ability to generate sustainable earnings.
Overall, the pretax margin of Moderna Inc has exhibited volatility and inconsistency over the years, which may indicate fluctuations in revenue generation, cost management, and overall financial health.
Peer comparison
Dec 31, 2024